Texas Biotechnology Reports Receipt
Selected Abstract
Texas Biotechnology Reports Receipt of an Approvable Letter for Use Of Argatroban in HIT Patients Undergoing Percutaneous Coronary Interventions.
HOUSTON, July 20 /PRNewswire/ -- Texas Biotechnology Corporation (Nasdaq: TXBI) announced that the U.S. Food & Drug Administration (FDA) has issued an approvable letter for a supplemental New Drug Application (sNDA) for Argatroban that further expands the treatable patient population to include ... July 20, 2001; PR Newswire
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
Texas Biotechnology Reports Receipt of an Approvable Letter for Use Of Argatroban in HIT Patients Undergoing Percutaneous Coronary Interventions.
2.
PR Newswire Southwest Summary, Friday, July 20, to 1:00 p.m. EDT.
3.
PR Newswire National Summary, Friday, July 20, 2001 to 10 A.M. EDT.
|
